Da Hee Han, PharmD

Most Recent Articles by Da Hee Han, PharmD

FDA to Review Tafamidis for Treatment of Transthyretin Amyloid Cardiomyopathy

FDA to Review Tafamidis for Treatment of Transthyretin Amyloid Cardiomyopathy

By

Tafamidis is an oral small molecule candidate that selectively binds at specific sites on the transthyretin tetramer to prevent destabilization of the transthyretin transport protein and formation of amyloid that causes ATTR-CM.

FDA-Approved Wearable Blood Pressure Monitor, Medical App Now Available

FDA-Approved Wearable Blood Pressure Monitor, Medical App Now Available

By

HeartGuide is designed as a wrist watch that uses the oscillometric cuff method, the standard for medical-grade personal blood pressure measurement.

Evolocumab Autoinjectors, Pre-Filled Syringes Now Available at Reduced List Price

Evolocumab Autoinjectors, Pre-Filled Syringes Now Available at Reduced List Price

By

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an on-body infusor with prefilled cartridge.

FDA Approval Expands Access to Factor Xa Inhibitor Antidote Andexxa

FDA Approval Expands Access to Factor Xa Inhibitor Antidote Andexxa

By

Andexxa was initially granted accelerated approval in May 2018 for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation was needed due to life-threatening or uncontrolled bleeding.

Rivaroxaban Supplemental New Drug Application Submitted to FDA for VTE Prophylaxis

Rivaroxaban Supplemental New Drug Application Submitted to FDA for VTE Prophylaxis

By

The sNDA submission was supported by Phase 3 data from the MAGELLAN and MARINER trials which assessed the use of rivaroxaban in preventing VTE in acute medically ill patients while hospitalized and immediately after discharge.

More Articles by Da Hee Han, PharmD

Sign Up for Free e-Newsletters